Our inter-institutional research team developed RS-D7, a novel NMDAR modulator/DAO inhibitor as a drug candidate for the treatment of ataxia/MSA. Based upon the core symptoms, we designedapplied preclinical mouse behavioral phenotyping techniquesclinical motor assessments to demonstrate the effectiveness of RS-D7our functional assays. RS-D7 offers multi-symptomatic relief.

Ataxia is an urgent unmet medical need. Our research team aims at developing novel NMDAR modulatorsexploring new indications for RS-D7. Comparing with TAK-831 from Takeda, we successfully applied preclinical mouse behavioral phenotyping techniquesclinical motor assessments to demonstrate the therapeutic effects of RS-D7 on the alleviation of ataxia-related motor deficits in miceclinical study.

1.We received several awards, e.g., Mentoring Program of Novartis Venture Fund, National Innovator AwardFuture Tech Exhibition of MOST.
2.Ataxia is an urgent unmet medical need. The future is wide open for investment in orphan drug.
3.IP protection is nearly completed. 
4.Our preclinical behavioral phenotypingclinical motor assessments can be directly applied for drug testing.
5.RS-D7 offers multi-symptomatic relief.